ArticleRespirology case reports2026
Renewed Response to Pembrolizumab After Salvage Radiotherapy for Oligoprogression in Advanced NSCLC: A Case Report.
Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Renewed Response to Pembrolizumab After Salvage Radiotherapy for Oligoprogression in Advanced NSCLC: A Case Report.Respirology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitor (ICI) rechallenge may benefit selected patients with NSCLC, but the role of local radiotherapy for oligoprogression and late same-agent rechallenge remains uncertain. We report a patient with Stage IVA lung adenocarcinoma and a programmed death-ligand 1 tumour proportion score of ≥ 75% who achieved a durable partial response to first-line pembrolizumab. After isolated left supraclavicular nodal oligoprogression in 2020, he received salvage radiotherapy and remained off systemic treatment for almost 5 years. In late 2025, multiple new right lower lobe nodules and pleural-based lesions appeared near the original primary site and enlarged on serial CT, prompting pembrolizumab rechallenge. CT in February 2026 showed a renewed partial response. This case suggests that rechallenge with pembrolizumab may remain reasonable at late relapse in carefully selected patients with durable initial benefit, limited progression controlled locally, a long treatment-free interval, and good performance status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.